This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
by Zacks Equity Research
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
REGNNegative Net Change PBYINegative Net Change CTMXPositive Net Change TILNegative Net Change
biotechs
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
REGNNegative Net Change PBYINegative Net Change NTLAPositive Net Change CTMXPositive Net Change
biotechs
Here's Why You Should Invest in Avadel (AVDL) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
REGNNegative Net Change PBYINegative Net Change AVDLNegative Net Change FUSNPositive Net Change
biotechs pharmaceuticals
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
by Zacks Equity Research
Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change SANANegative Net Change
biotechnology biotechs cell-therapy gene-editing gene-therapy medical pharmaceuticals
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
VRTXPositive Net Change CRSPNegative Net Change SLDBNegative Net Change
biotechnology biotechs pharmaceuticals
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
by Zacks Equity Research
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.
NVONegative Net Change SRPTPositive Net Change CTMXPositive Net Change
biotechs medical
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
by Zacks Equity Research
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
VRTXPositive Net Change SRPTPositive Net Change CRSPNegative Net Change
biotechs gene-therapy medical pharmaceuticals
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
REGNNegative Net Change BMYNegative Net Change EXELNegative Net Change RCUSPositive Net Change
biotechnology biotechs pharmaceuticals
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
RHHBYNegative Net Change SRPTPositive Net Change PBYINegative Net Change SLDBNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
by Zacks Equity Research
The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change PBYINegative Net Change
biotechnology biotechs pharmaceuticals
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
by Zacks Equity Research
Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
REGNNegative Net Change PBYINegative Net Change ACRSPositive Net Change CTMXPositive Net Change
biotechs
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
by Zacks Equity Research
Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
PBYINegative Net Change ADMAPositive Net Change APLSNegative Net Change ANNXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
REGNNegative Net Change PBYINegative Net Change CTMXPositive Net Change
biotechs
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
by Zacks Equity Research
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
NVONegative Net Change SRPTPositive Net Change ADAPPositive Net Change CTMXPositive Net Change
biotechs medical
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
by Zacks Equity Research
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
SNYNegative Net Change PBYINegative Net Change ADMAPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
AZNPositive Net Change NVONegative Net Change MRKNegative Net Change FUSNPositive Net Change
biotechs pharmaceuticals
Adicet (ACET) Stock Rallies 130% in a Month: Here's Why
by Zacks Equity Research
Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.
ACETPositive Net Change PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change
biotechnology biotechs medical pharmaceuticals
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
by Zacks Equity Research
Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
NVONegative Net Change SRPTPositive Net Change CTMXPositive Net Change IOVANegative Net Change
biotechs medical pharmaceuticals
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
by Zacks Equity Research
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
REGNNegative Net Change SRPTPositive Net Change ACADNegative Net Change VIRNegative Net Change
biotechnology biotechs pharmaceuticals
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
SRPTPositive Net Change PBYINegative Net Change CTMXPositive Net Change SLDBNegative Net Change
biotechs
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
REGNNegative Net Change NVONegative Net Change MRKNegative Net Change FUSNPositive Net Change
biotechs pharmaceuticals
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
by Zacks Equity Research
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
REGNNegative Net Change NVSNegative Net Change CYTKNegative Net Change ACADNegative Net Change
biotechnology biotechs pharmaceuticals
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
by Zacks Equity Research
Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
NVONegative Net Change SRPTPositive Net Change EBSNegative Net Change CTMXPositive Net Change
biotechs medical vaccines
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
by Zacks Equity Research
Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.
INONo Net Change PBYINegative Net Change ADMAPositive Net Change CHRSPositive Net Change
biotechnology biotechs dna-sequencing medical pharmaceuticals
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.
FOLDPositive Net Change PBYINegative Net Change CTMXPositive Net Change
biotechs